Which has better valuation and earnings, MRAI or CO?

Global Cord Blood has higher revenue and earnings than Marpai. Marpai is trading at a lower price-to-earnings ratio than Global Cord Blood, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Marpai $34.87M 1.83 -$28.75M -$0.87 N/A Global Cord Blood $1.24B 0.09 $79.04M $0.64 1.49

Is MRAI or CO more profitable?

Global Cord Blood has a net margin of 0.00% compared to Marpai's net margin of -85.70%. Company Net Margins Return on Equity Return on Assets Marpai -85.70% N/A -100.23% Global Cord Blood N/A N/A N/A

Do analysts prefer CYH or CO?

Community Health Systems presently has a consensus target price of $2.81, indicating a potential upside of 4.36%. Given Community Health Systems' stronger consensus rating and higher possible upside, equities analysts plainly believe Community Health Systems is more favorable than Global Cord Blood. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Community Health Systems 3 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Global Cord Blood 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend RZLT or CO?

Rezolute presently has a consensus target price of $9.38, suggesting a potential upside of 87.88%. Given Rezolute's stronger consensus rating and higher probable upside, research analysts clearly believe Rezolute is more favorable than Global Cord Blood. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rezolute 2 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.50 Global Cord Blood 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is RZLT or CO more profitable?

Global Cord Blood's return on equity of 0.00% beat Rezolute's return on equity. Company Net Margins Return on Equity Return on Assets Rezolute N/A -58.82% -54.48% Global Cord Blood N/A N/A N/A

Do analysts rate CO or VREX?

Varex Imaging has a consensus price target of $16.17, suggesting a potential upside of 48.05%. Given Varex Imaging's stronger consensus rating and higher probable upside, analysts plainly believe Varex Imaging is more favorable than Global Cord Blood. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Global Cord Blood 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Varex Imaging 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60

Do analysts prefer DCTH or CO?

Delcath Systems presently has a consensus target price of $22.17, indicating a potential upside of 81.40%. Given Delcath Systems' stronger consensus rating and higher possible upside, equities analysts plainly believe Delcath Systems is more favorable than Global Cord Blood. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Delcath Systems 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57 Global Cord Blood 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Global Cord Blood (CO) Competitors

$0.95 0.00 (0.00%)

As of 07/24/2026

Compare

CO vs. MRAI, CYH, RZLT, VREX, and DCTH

Should you buy Global Cord Blood stock or one of its competitors? MarketBeat compares Global Cord Blood with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Global Cord Blood include Marpai (MRAI), Community Health Systems (CYH), Rezolute (RZLT), Varex Imaging (VREX), and Delcath Systems (DCTH).

How does Global Cord Blood compare to Marpai?

Marpai (NASDAQ:MRAI) and Global Cord Blood (NYSE:CO) are both small-cap miscellaneous health & allied services, not elsewhere classified industry companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk and media sentiment.

Marpai has a beta of 4.92, meaning that its share price is 392% more volatile than the broader market. Comparatively, Global Cord Blood has a beta of 0.16, meaning that its share price is 84% less volatile than the broader market.

In the previous week, Marpai had 1 more articles in the media than Global Cord Blood. MarketBeat recorded 1 mentions for Marpai and 0 mentions for Global Cord Blood. Marpai's average media sentiment score of 0.00 equaled Global Cord Blood'saverage media sentiment score.

Company	Overall Sentiment
Marpai	Neutral
Global Cord Blood	Neutral

Global Cord Blood has higher revenue and earnings than Marpai. Marpai is trading at a lower price-to-earnings ratio than Global Cord Blood, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marpai	$34.87M	1.83	-$28.75M	-$0.87	N/A
Global Cord Blood	$1.24B	0.09	$79.04M	$0.64	1.49

Global Cord Blood has a net margin of 0.00% compared to Marpai's net margin of -85.70%.

Company	Net Margins	Return on Equity	Return on Assets
Marpai	-85.70%	N/A	-100.23%
Global Cord Blood	N/A	N/A	N/A

49.8% of Marpai shares are owned by institutional investors. 46.1% of Marpai shares are owned by insiders. Comparatively, 0.5% of Global Cord Blood shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Global Cord Blood beats Marpai on 6 of the 11 factors compared between the two stocks.

How does Global Cord Blood compare to Community Health Systems?

Community Health Systems (NYSE:CYH) and Global Cord Blood (NYSE:CO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, valuation and dividends.

Community Health Systems has a beta of 1.81, suggesting that its stock price is 81% more volatile than the broader market. Comparatively, Global Cord Blood has a beta of 0.16, suggesting that its stock price is 84% less volatile than the broader market.

In the previous week, Community Health Systems had 16 more articles in the media than Global Cord Blood. MarketBeat recorded 16 mentions for Community Health Systems and 0 mentions for Global Cord Blood. Global Cord Blood's average media sentiment score of 0.00 beat Community Health Systems' score of -0.37 indicating that Global Cord Blood is being referred to more favorably in the news media.

Company	Overall Sentiment
Community Health Systems	Neutral
Global Cord Blood	Neutral

Community Health Systems presently has a consensus target price of $2.81, indicating a potential upside of 4.36%. Given Community Health Systems' stronger consensus rating and higher possible upside, equities analysts plainly believe Community Health Systems is more favorable than Global Cord Blood.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Community Health Systems	3 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Global Cord Blood	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

85.0% of Community Health Systems shares are owned by institutional investors. 11.1% of Community Health Systems shares are owned by company insiders. Comparatively, 0.5% of Global Cord Blood shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Community Health Systems has a net margin of 2.10% compared to Global Cord Blood's net margin of 0.00%. Global Cord Blood's return on equity of 0.00% beat Community Health Systems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Community Health Systems	2.10%	-6.66%	0.62%
Global Cord Blood	N/A	N/A	N/A

Community Health Systems has higher revenue and earnings than Global Cord Blood. Community Health Systems is trading at a lower price-to-earnings ratio than Global Cord Blood, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Community Health Systems	$12.49B	0.03	$509M	$1.85	1.46
Global Cord Blood	$1.24B	0.09	$79.04M	$0.64	1.49

Summary

Community Health Systems beats Global Cord Blood on 11 of the 15 factors compared between the two stocks.

How does Global Cord Blood compare to Rezolute?

Rezolute (NASDAQ:RZLT) and Global Cord Blood (NYSE:CO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, analyst recommendations and dividends.

In the previous week, Rezolute had 6 more articles in the media than Global Cord Blood. MarketBeat recorded 6 mentions for Rezolute and 0 mentions for Global Cord Blood. Rezolute's average media sentiment score of 0.99 beat Global Cord Blood's score of 0.00 indicating that Rezolute is being referred to more favorably in the media.

Company	Overall Sentiment
Rezolute	Positive
Global Cord Blood	Neutral

83.0% of Rezolute shares are held by institutional investors. 14.8% of Rezolute shares are held by company insiders. Comparatively, 0.5% of Global Cord Blood shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Global Cord Blood has higher revenue and earnings than Rezolute. Rezolute is trading at a lower price-to-earnings ratio than Global Cord Blood, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rezolute	N/A	N/A	-$74.41M	-$0.82	N/A
Global Cord Blood	$1.24B	0.09	$79.04M	$0.64	1.49

Rezolute has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market. Comparatively, Global Cord Blood has a beta of 0.16, indicating that its share price is 84% less volatile than the broader market.

Rezolute presently has a consensus target price of $9.38, suggesting a potential upside of 87.88%. Given Rezolute's stronger consensus rating and higher probable upside, research analysts clearly believe Rezolute is more favorable than Global Cord Blood.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rezolute	2 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.50
Global Cord Blood	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Global Cord Blood's return on equity of 0.00% beat Rezolute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rezolute	N/A	-58.82%	-54.48%
Global Cord Blood	N/A	N/A	N/A

Summary

Rezolute beats Global Cord Blood on 8 of the 14 factors compared between the two stocks.

How does Global Cord Blood compare to Varex Imaging?

Global Cord Blood (NYSE:CO) and Varex Imaging (NASDAQ:VREX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, profitability, earnings and analyst recommendations.

Varex Imaging has a consensus price target of $16.17, suggesting a potential upside of 48.05%. Given Varex Imaging's stronger consensus rating and higher probable upside, analysts plainly believe Varex Imaging is more favorable than Global Cord Blood.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Global Cord Blood	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Varex Imaging	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Global Cord Blood has higher revenue and earnings than Varex Imaging. Varex Imaging is trading at a lower price-to-earnings ratio than Global Cord Blood, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Global Cord Blood	$1.24B	0.09	$79.04M	$0.64	1.49
Varex Imaging	$844.60M	0.54	-$70.30M	-$2.00	N/A

Global Cord Blood has a beta of 0.16, suggesting that its share price is 84% less volatile than the broader market. Comparatively, Varex Imaging has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market.

Global Cord Blood has a net margin of 0.00% compared to Varex Imaging's net margin of -9.64%. Varex Imaging's return on equity of 8.19% beat Global Cord Blood's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Global Cord Blood	N/A	N/A	N/A
Varex Imaging	-9.64%	8.19%	3.63%

In the previous week, Varex Imaging had 3 more articles in the media than Global Cord Blood. MarketBeat recorded 3 mentions for Varex Imaging and 0 mentions for Global Cord Blood. Varex Imaging's average media sentiment score of 1.45 beat Global Cord Blood's score of 0.00 indicating that Varex Imaging is being referred to more favorably in the news media.

Company	Overall Sentiment
Global Cord Blood	Neutral
Varex Imaging	Positive

Summary

Varex Imaging beats Global Cord Blood on 10 of the 15 factors compared between the two stocks.

How does Global Cord Blood compare to Delcath Systems?

Delcath Systems (NASDAQ:DCTH) and Global Cord Blood (NYSE:CO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

Delcath Systems has a beta of 0.49, meaning that its share price is 51% less volatile than the broader market. Comparatively, Global Cord Blood has a beta of 0.16, meaning that its share price is 84% less volatile than the broader market.

Delcath Systems has a net margin of 0.62% compared to Global Cord Blood's net margin of 0.00%. Delcath Systems' return on equity of 0.51% beat Global Cord Blood's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Delcath Systems	0.62%	0.51%	0.46%
Global Cord Blood	N/A	N/A	N/A

61.1% of Delcath Systems shares are owned by institutional investors. 19.4% of Delcath Systems shares are owned by insiders. Comparatively, 0.5% of Global Cord Blood shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Delcath Systems had 2 more articles in the media than Global Cord Blood. MarketBeat recorded 2 mentions for Delcath Systems and 0 mentions for Global Cord Blood. Delcath Systems' average media sentiment score of 0.94 beat Global Cord Blood's score of 0.00 indicating that Delcath Systems is being referred to more favorably in the media.

Company	Overall Sentiment
Delcath Systems	Positive
Global Cord Blood	Neutral

Global Cord Blood has higher revenue and earnings than Delcath Systems. Global Cord Blood is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Delcath Systems	$85.23M	4.95	$2.70M	$0.01	1,222.00
Global Cord Blood	$1.24B	0.09	$79.04M	$0.64	1.49

Delcath Systems presently has a consensus target price of $22.17, indicating a potential upside of 81.40%. Given Delcath Systems' stronger consensus rating and higher possible upside, equities analysts plainly believe Delcath Systems is more favorable than Global Cord Blood.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Delcath Systems	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Global Cord Blood	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Delcath Systems beats Global Cord Blood on 13 of the 16 factors compared between the two stocks.

Get Global Cord Blood News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CO vs. The Competition

Export

Metric	Global Cord Blood	health & allied services, not elsewhere classified Industry	Medical Sector	NYSE Exchange
Market Cap	$115.60M	$98.29M	$7.06B	$23.58B
Dividend Yield	N/A	N/A	2.67%	4.21%
P/E Ratio	1.49	0.74	27.14	30.98
Price / Sales	0.09	0.96	582.30	19.98
Price / Cash	4.19	4.19	49.81	32.09
Price / Book	0.15	0.15	10.28	4.73
Net Income	$79.04M	$25.15M	$3.60B	$1.07B
7 Day Performance	0.11%	17.06%	-1.27%	-0.45%
1 Month Performance	N/A	75.51%	-1.67%	-0.41%
1 Year Performance	33.94%	49.60%	18.25%	14.19%

Global Cord Blood Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CO Global Cord Blood	N/A	$0.95 flat	N/A	+72.9%	$115.60M	$1.24B	1.49	1,202
MRAI Marpai	N/A	$1.36 +81.3%	N/A	+80.9%	$36.19M	$34.87M	N/A	150	High Trading Volume
CYH Community Health Systems	1.5858 of 5 stars	$3.28 +2.7%	$3.41 +4.1%	-2.5%	$461.51M	$12.49B	0.95	57,000	News Coverage Earnings Report Analyst Forecast Options Volume
RZLT Rezolute	3.3246 of 5 stars	$4.75 -1.8%	$9.38 +97.6%	-20.8%	$456.22M	N/A	N/A	40	News Coverage Positive News
VREX Varex Imaging	4.2574 of 5 stars	$10.77 +1.9%	$16.17 +50.1%	+39.1%	$453.00M	$857.50M	N/A	2,400	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:CO) was last updated on 7/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Global Cord Blood (CO) Competitors

CO vs. MRAI, CYH, RZLT, VREX, and DCTH

How does Global Cord Blood compare to Marpai?

Summary

How does Global Cord Blood compare to Community Health Systems?

Summary

How does Global Cord Blood compare to Rezolute?

Summary

How does Global Cord Blood compare to Varex Imaging?

Summary

How does Global Cord Blood compare to Delcath Systems?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CO vs. The Competition

Global Cord Blood Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Global Cord Blood (CO) Competitors

CO vs. MRAI, CYH, RZLT, VREX, and DCTH

How does Global Cord Blood compare to Marpai?

Which has more volatility and risk, MRAI or CO?

Does the media favor MRAI or CO?

Which has better valuation and earnings, MRAI or CO?

Is MRAI or CO more profitable?

Do institutionals & insiders have more ownership in MRAI or CO?

Summary

How does Global Cord Blood compare to Community Health Systems?

Which has more risk & volatility, CYH or CO?

Does the media prefer CYH or CO?

Do analysts prefer CYH or CO?

Do insiders and institutionals believe in CYH or CO?

Is CYH or CO more profitable?

Which has preferable valuation & earnings, CYH or CO?

Summary

How does Global Cord Blood compare to Rezolute?

Does the media favor RZLT or CO?

Do insiders & institutionals have more ownership in RZLT or CO?

Which has higher valuation & earnings, RZLT or CO?

Which has more volatility and risk, RZLT or CO?

Do analysts recommend RZLT or CO?

Is RZLT or CO more profitable?

Summary

How does Global Cord Blood compare to Varex Imaging?

Do analysts rate CO or VREX?

Which has higher valuation and earnings, CO or VREX?

Which has more risk & volatility, CO or VREX?

Is CO or VREX more profitable?

Does the media favor CO or VREX?

Summary

How does Global Cord Blood compare to Delcath Systems?

Which has more volatility and risk, DCTH or CO?

Is DCTH or CO more profitable?

Do insiders & institutionals have more ownership in DCTH or CO?

Does the media prefer DCTH or CO?

Which has higher earnings and valuation, DCTH or CO?

Do analysts prefer DCTH or CO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CO vs. The Competition

Global Cord Blood Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools